PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Annals of Oncology10.1093/annonc/mdu334.64201425iv230Third-Line Weekly Docetaxel Chemotherapy in Advanced Gastric Cancer Who Failed Previous Fluoropyrimidine and Irinotecan or Oxaliplatin-Based ChemotherapiesG.J. Lee, Y.S. Hong, S.Y. Rohhttps://api.elsevier.com/content/article/PII:S0923753419521329?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419521329?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/25/suppl_4/iv230/9690521/mdu334.64.pdf
Cancer Research and Treatment10.4143/crt.2012.44.4.2352012444235-241Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based ChemotherapiesMin Jeong Lee, In Gyu Hwang, Joung-Soon Jang, Jin Hwa Choi, Byeong-Bae Park, Myung Hee Chang, Seung Tae Kim, Se Hoon Park, Myoung Hee Kang, Jung Hun Kanghttp://www.e-crt.org/upload/pdf/crt-44-235.pdf, http://www.e-crt.org/upload/pdf/crt-44-235.pdf
Annals of Oncology10.1016/s0923-7534(20)30246-5201223iv42P-0039 Irinotecan as a Second/Third Line Chemotherapy in Gastric Cancer Patients who Failed S-1-Based TreatmentYasuhiro Kodera, Norifumi Ohashi, Yoshinari Mochizuki, Kiyoshi Ishigure, Chie Tanaka, Suguru Yamada, Daisuke Kobayashi, Tsutomu Fujii, Michitaka Fujiwara, Seiji Itohttps://api.elsevier.com/content/article/PII:S0923753420302465?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420302465?httpAccept=text/plain
Cancer Research and Treatment10.4143/crt.2015.4522017491255-262Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-AnalysisYo-Han Cho, So Young Yoon, Soo-Nyung Kimhttp://e-crt.org/upload/pdf/crt-2015-452.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2015.452, http://www.e-crt.org/upload/pdf/crt-2015-452.pdf
Thoracic Cancer10.1111/1759-7714.12064201452169-173Docetaxel-based chemotherapy as second-line regimen for advanced thymic carcinomaZhengbo Song, Xinmin Yu, Chunxiao He, Beibei Zhang, Yiping Zhanghttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2F1759-7714.12064, http://onlinelibrary.wiley.com/wol1/doi/10.1111/1759-7714.12064/fullpdf
Lung Cancer10.1016/s0169-5002(03)91662-x200341S5O-4 A randomized phase II study of docetaxel versus docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first line chemotherapyH.J.M. Groen, F.M. Wachters, B. Biesma, F.M.N.H. Schramel, J.A. Stigt, E.F. Smithttps://api.elsevier.com/content/article/PII:S016950020391662X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S016950020391662X?httpAccept=text/plain
Chest10.1378/chest.129.4.1031200612941031-1038A Randomized Trial of Different Docetaxel Schedules in Non-small Cell Lung Cancer Patients Who Failed Previous Platinum-Based ChemotherapyYuh-Min Chen, Jen-Fu Shih, Reury-Perng Perng, Chun-Ming Tsai, Jacqueline Whang-Penghttps://api.elsevier.com/content/article/PII:S0012369215388218?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0012369215388218?httpAccept=text/plain
Medical Oncology10.1007/s12032-010-9755-1201028S1291-294Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapyDuk Joo Lee, Jeeyun Lee, Ha Yeon Lee, Taekyu Lim, Su Jin Lee, Seong Yoon Yi, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Young Suk Parkhttp://link.springer.com/content/pdf/10.1007/s12032-010-9755-1.pdf, http://link.springer.com/article/10.1007/s12032-010-9755-1/fulltext.html, http://link.springer.com/content/pdf/10.1007/s12032-010-9755-1
Chemotherapy10.1159/0003561582013594273-2795-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based TherapyMin Geun Lee, Sang Hyub Lee, Seung June Lee, Yoon Suk Lee, Jin-Hyeok Hwang, Ji Kon Ryu, Yong-Tae Kim, Dong Uk Kim, Sang Myung Woohttps://www.karger.com/Article/Pdf/356158, http://www.karger.com/Article/Pdf/356158
Cancer Chemotherapy and Pharmacology10.1007/s00280-014-2416-x2014734847-855The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancerGoro Nakayama, Chie Tanaka, Keisuke Uehara, Naoki Mashita, Naomi Hayashi, Daisuke Kobayashi, Mitsuro Kanda, Suguru Yamada, Tsutomu Fujii, Hiroyuki Sugimoto, Masahiko Koike, Shuji Nomoto, Michitaka Fujiwara, Yuich Ando, Yasuhiro Koderahttp://link.springer.com/content/pdf/10.1007/s00280-014-2416-x.pdf, http://link.springer.com/article/10.1007/s00280-014-2416-x/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00280-014-2416-x